Crossmark

Effects of switching from agalsidase−α to agalsidase−β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report

Crossref DOI link: https://doi.org/10.1007/s13730-023-00843-1

Published Online: 2023-12-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shima, Hisato https://orcid.org/0000-0003-3918-4735
Tsukimura, Takahiro

Shiga, Tomoko

Togawa, Tadayasu

Sakuraba, Hitoshi

Doi, Toshio

Ikeda, Yuka

Okamoto, Takuya

Yoshikawa, Yukari

Kimura, Takehiko

Iwase, Takashi

Inoue, Tomoko

Tashiro, Manabu

Okada, Kazuyoshi

Minakuchi, Jun
Funding

Funding for this research was provided by:

Dainippon Sumitomo Pharma
License Information

Text and Data Mining valid from 2023-12-22

Version of Record valid from 2023-12-22
More Information

Article History

Received: 30 October 2023

Accepted: 28 November 2023

First Online: 22 December 2023

Declarations

:

: The authors declare no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee, and with the 1964 Helsinki Declaration and its later amendments and comparable ethical standards.

: Informed consent was obtained from the individual participant included in the study.

Document is current

Any future updates will be listed below